TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • Sustainability
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Industry News Articles > Titanium dioxide declared unsafe in food products

Titanium dioxide declared unsafe in food products

Titanium dioxide declared unsafe in food products, raising concerns for drug manufacturers

Author: Thomas Eberwein

Concerns about the safety of titanium dioxide as a food additive could potentially create significant challenges for the pharmaceutical industry. A May 2021 evaluation from the European Food Safety Authority (EFSA) concluded that it was not possible to exclude genotoxicity concerns after consumption of titanium dioxide particles.

Genotoxicity refers to the ability of a substance to damage the genetic information within cells, causing mutations and potentially leading to cancer. However, three European associations focused on human medicines – Medicines for Europe, the European Federation of Pharmaceutical Industries and Associations (EFPIA), and the Association of the European Self-Care Industry (AESGP) – have noted that titanium dioxide (TiO2) has not been found to induce gene mutations during in vitro/in vivo studies.

What then, are the implications of the EFSA decision?

While EFSA’s opinion currently only affects food products, it will likely raise questions regarding the use of titanium dioxide in other products, including medicines.

The medicines associations have said several open questions need to be addressed to inform the benefit/risk assessment of TiO2 in pharmaceuticals. Perhaps key among these is the potential for any ban on the use of TiO2 to affect availability of products in the EU.

An August 2020 survey conducted by the three associations of companies that produce prescription and/or non-prescription drugs, found that more than 90 percent of oral dosage forms contain TiO2, typically containing less than 1mg per product per day.

If companies were required to remove TiO2 it would require reformulation, which could take years for each product, depending on the need for studies to determine stability, bioequivalence, and other formulation requirements. A study by the three associations estimates replacing TiO2 across the whole portfolio would take up to 10 years, given all the products that would need to be reformulated.

Furthermore, the medicines bodies note that other global regulators currently do not see safety concerns with using TiO2 in medicines, so removal of TiO2 from use in medicines would require new formulations to be developed for products sold in the EU but not in the rest of the world. This could potentially further limit access to medicines for EU patients, since if production is unsustainable, companies are likely to withdraw their products from the European market.

Addressing adherence

Non-adherence to medications is a common problem, with the World Health Organization estimating that 50 percent of patients with chronic conditions deviate from their treatments.

According to a presentation from the three human medicines associations, titanium dioxide is vital for the optimum appearance of tablets and capsules, and therefore plays a significant role in patient compliance. The industry bodies note that, to the best of their knowledge, no other material shows the same properties as TiO2, such as opacity, whiteness, inertness, protection from UV light and the finish/smoothness of the resulting product.

To achieve the same or similar level of opaqueness, manufacturers would likely have to use larger amounts of other colorants. In addition, alternatives, especially if used in larger amounts, could have greater reactivity with API or other excipients. Current alternatives include calcium carbonate, talc and starch; however, all have downsides, according to the assessment from the three associations. Since calcium carbonate is sourced by mining on land and coral reefs it is not an environmentally friendly option, and its alkaline properties could react with the active ingredient. Talc is also a mined mineral and managing elemental impurity levels and ensuring the absence of asbestos adds complexity. Corn starch is the preferred ingredient due to whiteness compared to other starches, but sourcing GMO-certified free corn starch could present a challenge for the European market.

A further challenge is cost. According to assessments carried out by the three associations, based on the joint association survey, each reformulation could cost companies between €500,000 and €1.5 million.

In light of the EFSA decision, medicines associations are seeking advice from the European Medicines Agency on any likely decision about drug products. Questions raised include whether EMA will conduct an impact assessment, including collecting data from manufacturers and suppliers; and how any safety assessment will be conducted and plans to engage industry in such an exercise. And they will be seeking assurances around public communication and whether national regulators will be included in the line of communication.

If you would like to discuss the issues of titanium dioxide in modern pharmaceuticals, please reach out to our industry experts – contact@pharmalex.com

Contact us
Related posts
Why collaboration and an Integrated Product Development program are key to successful drug development
Why collaboration and an Integrated Product Development program are key to successful drug development
14th June 2022
Key Takeaways from the PDA Europe Annex 1 Workshop
Key Takeaways from the PDA Europe Annex 1 Workshop
7th June 2022
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Search
Upcoming Events

September 11 - 13th, 2022

2022 RAPS Convergence, Phoenix, USA – 11 to 13 September 2022

Visit us at booth 507

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
pharmalexglobal PharmaLex @pharmalexglobal ·
11 Aug

A Case Study in global End-to-End HQ #Outsourcing: ➡  Download the case study to discover more details: https://lnkd.in/ex_-jpxP

#pharmaindustry

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • There was a close relationship between the regulatory strategy and the writing activities. You developed a fine-tuned regulatory strategy which will be a key factor to smooth the approval of our dossier.

    Large Pharma, Global
    VP Regulatory Strategy
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for